UNSPSC 51162315: Acetaminophen/chlorpheniramine/phenylpropanolamine/salicylamide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF) which falls under VA Drug Class RE599. This VA Drug Class (RE599) classifies this compound as belonging to the group COLD REMEDIES, OTHER.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51162315 Acetaminophen/chlorpheniramine/phenylpropanolamine/salicylamide is a Commodity code that in recent state and local procurement activity covers parenteral pharmaceutical products and medical supplies — including intravenous solutions, parenteral nutrition preparations, naloxone, and drug deactivation systems — supplied to correctional facilities and public health programs. State agencies, counties, and special-purpose health districts are the primary issuing bodies. The Washington State Department of Corrections solicited parenteral products and services through RFQQK13020, a competitive quote process requesting bids for IV solutions, nutrition preparations, and controlled substances to supply eight correctional facilities across three regions (West, Central, and East) with response due October 7, 2026; DOC anticipates awarding up to three contractors per region for an initial term running November 26, 2026 through June 30, 2030. The code also encompasses broader pharmaceutical procurement such as naloxone and drug deactivation systems; Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 for annual procurement of 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly delivery to its Community Health Building.

Recent activity spans Washington State and Florida, with the Washington solicitation emphasizing stringent delivery requirements (PN bags within 24 hours of order; other parenteral products within 8 hours), documented clinical preparation experience, and state set-aside aspirations for small, minority-owned, women-owned, and veteran-owned businesses certified under Washington's Chapter 39.19 RCW. Insurance requirements are substantial, including Commercial General Liability ($1 million per occurrence / $2 million aggregate), Professional Liability ($2 million per occurrence / aggregate), and Cyber Liability ($2 million per occurrence / aggregate). The Seminole County naloxone procurement operates on a fixed-fee basis with an initial two-year term and one-year renewal option, requiring E-Verify compliance and potentially funded through FEMA with associated federal compliance obligations. Both solicitations reflect correctional and public-health demand for pharmaceutical products with high delivery-speed and quality-assurance requirements.